Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-05-14T23:47:52.013Z Has data issue: false hasContentIssue false

Chapter 9 - Pathology of the Prostate after Treatment

Published online by Cambridge University Press:  04 November 2017

Antonio Lopez-Beltran ,
Liang Cheng ,
Rodolfo Montironi  and
Maria Rosaria Raspollini
Antonio Lopez-Beltran
Affiliation:
Cordoba University Medical School, Spain
Liang Cheng
Affiliation:
Indiana University School of Medicine, USA
Rodolfo Montironi
Affiliation:
University of Ancona, Italy
Maria Rosaria Raspollini
Affiliation:
University Hospital Careggi, Florence, Italy
Get access
Type
Chapter
Information
Pathology of the Prostate
An Algorithmic Approach
 , pp. 114 - 126
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Evans, AJ, Ryan, P, van der Kwast, T. Treatment Effects in the Prostate Including Those Associated with Traditional and Emerging Therapies. Adv Anat Pathol. 2011; 18(4): 281–93.CrossRefGoogle ScholarPubMed
Srigley, JR, Delahunt, B, Evans, AJ. Therapy-associated Effects in the Prostate Gland. Histopathology. 2012; 60(1): 153–65.CrossRefGoogle ScholarPubMed
Bono, AV, Mazzucchelli, R, Ferrari, I, et al. Bicalutamide 50 mg Monotherapy in Patients with Isolated High-grade PIN: Findings in Repeat Biopsies at 6 Months. J Clin Pathol. 2007; 60(4): 443–46.Google Scholar
Zattoni, F. Prostate Cancer: What Are the News in Hormonal Therapy? The Role of GnRH Antagonists. Arch Ital Urol Androl. 2012; 84 (3): 111–16.Google Scholar
Humphrey, PA. Treatment Effects. In: Prostate Pathology. Humphrey, PA (Ed.), ASCP PRESS. Chicago, USA. 2003; 456–76.Google Scholar
Montironi, R, Schulman, CC. Pathological Changes in Prostate Lesions after Androgen Manipulation. J Clin Pathol. 1998; 51 (1): 5–12.Google Scholar
Petraki, CD, Sfikas, CP. Histopathological Changes Induced by Therapies in the Benign Prostate and Prostate Adenocarcinoma. Histol Histopathol. 2007; 22 (1): 107–18.Google Scholar
Têtu, B. Morphological Changes Induced by Androgen Blockade in Normal Prostate and Prostatic Carcinoma. Best Pract Res Clin Endocrinol Metab. 2008; 22(2): 271–83.CrossRefGoogle ScholarPubMed
Brawer, MK. Hormonal therapy for prostate cancer. Rev Urol. 2006; 8(2): S35–S47.Google ScholarPubMed
Crawford, ED. Hormonal Therapy of Prostate Cancer: Historical Approaches. Rev Urol. 2006; 6(7): S3–S11.Google Scholar
Civantos, F, Marcial, MA, Banks, ER, et al. Pathology of Androgen Deprivation Therapy in Prostate Carcinoma: A Comparative Study of 173 Patients. Cancer. 1995; 75(7): 1634–41.Google Scholar
Têtu, B, Srigley, JR, Boivin, JC, et al. Effect of Combination Endocrine Therapy (LHRH Agonist and Flutamide) on Normal Prostate and Prostatic Adenocarcinoma. A Histopathologic and Immunohistochemical Study. Am J Surg Pathol. 1991; 15(2): 111–20.CrossRefGoogle ScholarPubMed
Andriole, G, Bostwick, D, Civantos, F, et al. The Effects of 5alpha-Reductase Inhibitors on the Natural History, Detection and Grading of Prostate Cancer: Current State of Knowledge. J Urol. 2005; 174(6): 2098–104.Google Scholar
Thompson, IM, Goodman, PJ, Tangen, CM, et al. The Influence of Finasteride on the Development of Prostate Cancer. N Engl J Med. 2003; 349(3): 215–24.Google Scholar
Wilt, TJ, Macdonald, R, Hagerty, K, et al. 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: An updated Cochrane Systematic Review. BJU Int. 2010; 106(10): 1444–51.CrossRefGoogle ScholarPubMed
Bostwick, DG, Qian, J. Effect of Androgen Deprivation Therapy on Prostatic Intraepithelial Neoplasia. Urology. 2001; 58(2): 91–93.CrossRefGoogle Scholar
Ferguson, J, Zincke, H, Ellison, E, Bergstrahl, E, Bostwick, DG. Decrease of Prostatic Intraepithelial Neoplasia (PIN) Following Androgen Deprivation Therapy in Patients with Stage T3 Carcinoma Treated by Radical Prostatectomy. Urology. 1994; 44(1): 91–95.Google Scholar
Vaillancourt, L, Tetu, B, Fradet, Y, et al. Effect of Neoadjuvant Endocrine Therapy (Combined Androgen Blockade) on Normal Prostate and Prostatic Carcinoma. J Surg Pathol. 1996; 20: 86–93.Google Scholar
Montironi, R, Magi Galluzzi, C, Muzzonigro, G, Prete, E, Polito, M, Fabris, G. Effect of Combination Endocrine Therapy (LHRH Agonist and Flutamide) on Normal Prostate, Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma. J Clin Pathol. 1994; 47(10): 906–13.CrossRefGoogle ScholarPubMed
Dhom, G, Degro, S. Therapy of Prostatic Cancer and Histopathologic Follow-up. Prostate. 1982; 3(6): 531–42.CrossRefGoogle ScholarPubMed
Selli, C, Montironi, R, Bono, A, et al. PROSIT Study Group. Effects of Complete Androgen Blockade for 12 and 24 Weeks on the Pathological Stage and Resection Margin Status of Prostate Cancer. J Clin Pathol. 2002; 55(7): 508–13.Google Scholar
Armas, OA, Aprikian, A, Melamed, J, et al. Clinical and Pathobiological Effects of Neoadjuvant Total Androgen Ablation Therapy in Clinically Localized Prostatic Carcinoma. Am J Surg Pathol. 1994; 18(10): 979–91.Google Scholar
Magi Galluzzi, C, Montironi, R, Giannulis, I, Diamanti, L, Scarpelli, M. Prostatic Invasive Adenocarcinoma. Effect of Combination Endocrine Therapy (LHRH Agonist and Flutamide) on the Expression and Location of Proliferating Cell Nuclear Antigen (PCNA). Pathol Res Pract. 1993; 189(10): 1154–60.Google ScholarPubMed
Minardi, D, Galosi, AB, Giannulis, I, Montironi, R, Polito, M, Muzzonigro, G. Comparison of Proliferating Cell Nuclear Antigen Immunostaining in Lymph Node Metastases and Primary Prostate Adenocarcinoma after Neoadjuvant Androgen Deprivation Therapy. Scand J Urol Nephrol. 2004; 38(1): 19–25.Google Scholar
Montironi, R, Magi Galluzzi, C, Fabris, G. Apoptotic Bodies in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma Following Total Androgen Ablation. Pathol Res Pract. 1995; 191(9): 873–80.Google Scholar
Murphy, WM, Soloway, MS, Barrows, GH. Pathologic Changes Associated with Androgen Deprivation Therapy for Prostate Cancer. Cancer. 1991; 68(4): 821–28.Google Scholar
Reuter, VE. Pathological Changes in Benign and Malignant Prostatic Tissue Following Androgen Deprivation Therapy. Urology. 1997; 49(3A): 16–22.Google Scholar
Smith, DM, Murphy, WM. Histologic Changes in Prostate Carcinomas Treated with Leuprolide (Luteinizing Hormone-releasing Hormone Effect). Distinction from Poor Tumor Differentiation. Cancer. 1994; 73(5): 1472–77.3.0.CO;2-M>CrossRefGoogle ScholarPubMed
Van de Voorde, WM, Elgamal, AA, Van Poppel, HP, Verbeken, EK, Baert, LV, Lauweryns, JM. Morphologic and Immunohistochemical Changes in Prostate Cancer after Preoperative Hormonal Therapy. Cancer. 1994; 74(12): 3164–75.Google Scholar
Akakura, K, Bruchovsky, N, Goldenberg, SL, Rennie, PS, Buckley, AR, Sullivan, LD. Effects of Intermittent Androgen Suppression on Androgen-dependent Tumors. Cancer. 1993; 71(9): 2782–90.3.0.CO;2-Z>CrossRefGoogle ScholarPubMed
Efstathiou, E, Abrahams, NA, Tibbs, RF, et al. Morphologic Characterization of Preoperatively Treated Prostate Cancer: Toward a Post-therapy Histologic Classification. Eur Urol. 2010; 57(6): 1030–38.Google Scholar
Lucia, MS, Epstein, JI, Goodman, PJ, et al. Finasteride and High-grade Prostate Cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007; 99(18): 1375–83.CrossRefGoogle ScholarPubMed
Rubin, MA, Allory, Y, Molinie´, V, et al. Effects of Long-term Finasteride Treatment on Prostate Cancer Morphology and Clinical Outcome. Urology. 2005; 66(5): 930–34.CrossRefGoogle ScholarPubMed
Scattoni, V, Montironi, R, Mazzucchelli, R, et al. Pathological Changes of High-grade Prostatic Intraepithelial Neoplasia and Prostate Cancer after Monotherapy with Bicalutamide 150 mg. BJU Int. 2006. 98(1): 54–58.Google Scholar
Bullock, MJ, Srigley, JR, Klotz, LH, Goldenberg, SL. Pathologic Effects of Neoadjuvant Cyproterone Acetate on Nonneoplastic Prostate, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma. A Detailed Analysis of Radical Prostatectomy Specimens from a Randomized Trial. Am J Surg Pathol. 2002; 26(11): 1400–13.CrossRefGoogle ScholarPubMed
Schulman, CC, Wildschutz, T, Zlotta, AR. Neoadjuvant Hormonal Treatment Prior to Radical Prostatectomy: Facts and Questions. Eur Urol. 1997; 32(3): 41–47.Google Scholar
Gleave, ME, Goldenberg, SL, Jones, EC, Bruchovsky, N, Kinahan, J, Sullivan, LD. Optimal Duration of Neoadjuvant Androgen Withdrawal Therapy before Radical Prostatectomy in Clinically Confined Prostate Cancer. Sem Urol Oncol. 1996; 14(2): 39–47.Google Scholar
Bazinet, M, Zheng, W, Begin, LR, Aprikian, AG, Karakiewicz, PI, Elhilali, MM. Morphologic Changes Induced by Neoadjuvant Androgen Ablation May Result in Underdetection of Positive Surgical Margins and Capsular Involvement by Prostatic Adenocarcinoma. Urology. 1997; 49(5): 721–25.Google Scholar
Gould, VE, Doljanskaia, V, Gooch, GT, Bostwick, DG. Stability of the Glycoprotein A-80 in Prostatic Carcinoma Subsequent to Androgen Deprivation Therapy. Am J Surg Pathol. 1997; 21(3): 319–26.CrossRefGoogle ScholarPubMed
Abbas, F, Scardino, PT. Why Neoadjuvant Androgen Deprivation Prior to Radical Prostatectomy is Unnecessary. Urol Clin North Am. 1996; 23(4): 587–604.CrossRefGoogle ScholarPubMed
Schulman, CC. Neoadjuvant Androgen Blockade Prior to Prostatectomy: A Retrospective Study and Critical Review. Prostate. 1994; 5: 9–13.CrossRefGoogle ScholarPubMed
Watson, RB, Soloway, MS. Neoadjuvant Hormonal Treatment before Radical Prostatectomy. Sem Urol Oncol. 1996; 14(2): 48–56.Google Scholar
Heidenreich, A, Richter, S, Thuer, D. Prognostic Parameters, Complications, and Oncologic and Functional Outcome of Salvage Radical Prostatectomy for Locally Recurrent Prostate Cancer after 21st-century Radiotherapy. Eur Urol. 2010; 57(3): 437–43.Google Scholar
Böcking, A, Auffermann, W. Cytological Grading of Therapy-induced Tumor Regression in Prostatic Carcinoma: Proposal of a New System. Diagn Cytopathol. 1987; 3(2): 108–11.Google Scholar
Crook, JM, Bahadur, YA, Robertson, SJ, Perry, GA, Esche, BA. Evaluation of Radiation Effect, Tumor Differentiation and Prostate Specific Antigen Staining in Sequential Prostate Biopsies after External Beam Radiotherapy for Patients with Prostate Carcinoma. Cancer. 1997; 79(1): 81–89.Google Scholar
Crook, JM, Malone, S, Perry, G, et al. Twenty-four Month Postradiation Prostate Biopsies are Strongly Predictive of 7-year Disease Free Survival: Results from a Canadian Randomized Trial. Cancer. 2009; 115(3): 673–79.Google Scholar
O’Brien, C, True, LD, Higano, CS, Rademacher, BL, Garzotto, M, Beer, TM. Histologic Changes Associated with Neoadjuvant Chemotherapy Are Predictive of Nodal Metastases in Patients with High-risk Prostate Cancer. Am J Clin Pathol. 2010; 133(4): 654–61.CrossRefGoogle ScholarPubMed
Falconieri, G, Lugnani, F, Zanconati, F, Signoretto, D, Di Bonito, L. Histopathology of the Frozen Prostate. The Microscopic Bases of Prostatic Carcinoma Cryoablation. Pathol Res Pract. 1996; 192(6): 579–87.Google Scholar
Galosi, AB, Lugnani, F, Muzzonigro, G. Salvage Cryosurgery for Recurrent Prostate Carcinoma after Radiotherapy. J Endourol. 2007; 21(1): 1–7.Google Scholar
Morgenstern, N, Ro, JY, Batts, P, et al. Prostate Cryotherapy: Chronological Post-therapy Histologic Changes with Clinical Correlation. Mod Pathol. 1997; 10: 83A.Google Scholar
Shabaik, A, Wilson, S, Bidair, M, et al. Pathologic Changes in Prostate Biopsies Following Cryoablation Therapy of Prostate Carcinoma. J Urol Pathol. 1995; 3: 183–93.Google Scholar
Armstrong, AJ, George, DJ. New Drug Development in Metastatic Prostate Cancer. Urol Oncol. 2008; 26 (4): 430–37.Google Scholar
Gerritsen, WR. The Evolving Role of Immunotherapy in Prostate Cancer. Ann Oncol. 2012; 2(8): viii22–7.Google Scholar
Cheng, ML, Fong, L. Beyond Sipuleucel-T: Immune Approaches to Treating Prostate Cancer. Curr Treat Options Oncol. 2014 Jan 10; [Epub ahead of print].Google Scholar
Nguyen, HM, Ruppender, N, Zhang, X, et al. Cabozantinib Inhibits Growth of Androgen-sensitive and Castration-resistant Prostate Cancer and Affects Bone Remodeling. PLoS One. 2013; 8(10): e78881.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×